E-LIB Suche - Ergebnisse für: Gunnar Kvalheim

1

ITOC2 – 022. Vaccination with next-generation dendritic cel..:

Frauke, Schnorfeil ; Felix, Lichtenegger ; Christiane, Geiger...
European Journal of Cancer. 51 (2015) - p. S8 , 2015

Link: https://doi.org/10.1016/..

2

The Agaricus blazei-based mushroom extract, AndosanTM, has ..:

Geir, Tjonnfjord ; Liv, Osnes ; Gunnar, Kvalheim...
Frontiers in Immunology. 4 (2013) - p. , 2013

Link: https://doi.org/10.3389/..

3

Efficient CAR T cell targeting of the CA125 extracellular r..:

Casey, Nicholas P ; Kleinmanns, Katrin ; Forcados, Christopher...
Journal for ImmunoTherapy of Cancer. 12 (2024) 4 - p. e008179 , 2024

Link: https://doi.org/10.1136/..

4

Transient TCR-based T cell therapy in a patient with advanc..:

Maggadottir, Solrun Melkorka ; Dueland, Svein ; Mensali, Nadia...
Molecular Therapy. 32 (2024) 6 - p. 2021-2029 , 2024

Link: https://doi.org/10.1016/..

5

CD37 is a safe chimeric antigen receptor target to treat ac..:

Caulier, Benjamin ; Joaquina, Sandy ; Gelebart, Pascal...
Cell Reports Medicine. 5 (2024) 6 - p. 101572 , 2024

Link: https://doi.org/10.1016/..

6

ALPL-1 is a target for chimeric antigen receptor therapy in..:

Mensali, Nadia ; Köksal, Hakan ; Joaquina, Sandy...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

7

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintena..:

Fløisand, Yngvar ; Remberger, Mats ; Bigalke, Iris...
Leukemia. 37 (2023) 9 - p. 1842-1849 , 2023

Link: https://doi.org/10.1038/..

8

A phase I prospective, non-randomized trial of autologous d..:

Thomsen, Liv Cecilie Vestrheim ; Honoré, Alfred ; Reisæter, Lars Anders Rokne...
Cancer Immunology, Immunotherapy. 72 (2023) 7 - p. 2357-2373 , 2023

Link: https://doi.org/10.1007/..

9

A phase I/II escalation trial design T-RAD: Treatment of me..:

Maggadóttir, Sólrún Melkorka ; Kvalheim, Gunnar ; Wernhoff, Patrik...
Frontiers in Oncology. 12 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

10

Combinatorial CAR design improves target restriction:

Köksal, Hakan ; Dillard, Pierre ; Juzeniene, Asta...
Journal of Biological Chemistry. 296 (2021) - p. 100116 , 2021

Link: https://doi.org/10.1074/..

11

Targeting KRAS mutations with HLA class II-restricted TCRs ..:

Dillard, Pierre ; Casey, Nicholas ; Pollmann, Sylvie...
OncoImmunology. 10 (2021) 1 - p. , 2021

Link: https://doi.org/10.1080/..

12

"Built‐in" PD‐1 blocker to rescue NK‐92 activity from PD‐L1..:

Mensali, Nadia ; Dillard, Pierre ; Fayzullin, Artem...
The FASEB Journal. 35 (2021) 9 - p. , 2021

Link: https://doi.org/10.1096/..

13

Targeting Telomerase with an HLA Class II-Restricted TCR fo..:

Dillard, Pierre ; Köksal, Hakan ; Maggadottir, Solrun Melkorka...
Molecular Therapy. 29 (2021) 3 - p. 1199-1213 , 2021

Link: https://doi.org/10.1016/..

14

Long Term Follow up of a "Fast-DC" Immunotherapy Against WT..:

Floisand, Yngvar ; Remberger, Mats ; Bigalke, Iris...
Transplantation and Cellular Therapy. 27 (2021) 3 - p. S337 , 2021

Link: https://doi.org/10.1016/..

15

Long‐term first‐in‐man Phase I/II study of an adjuvant dend..:

Tryggestad, Anne M. A. ; Axcrona, Karol ; Axcrona, Ulrika...
The Prostate. 82 (2021) 2 - p. 245-253 , 2021

Link: https://doi.org/10.1002/..